These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 18201551)

  • 1. Anticancer agent CHS-828 inhibits cellular synthesis of NAD.
    Olesen UH; Christensen MK; Björkling F; Jäättelä M; Jensen PB; Sehested M; Nielsen SJ
    Biochem Biophys Res Commun; 2008 Mar; 367(4):799-804. PubMed ID: 18201551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents.
    Pogrebniak A; Schemainda I; Azzam K; Pelka-Fleischer R; Nüssler V; Hasmann M
    Eur J Med Res; 2006 Aug; 11(8):313-21. PubMed ID: 17052966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data.
    von Heideman A; Berglund A; Larsson R; Nygren P
    Cancer Chemother Pharmacol; 2010 May; 65(6):1165-72. PubMed ID: 19789873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological evaluation of isosteric analogues of FK866, an inhibitor of NAD salvage.
    Galli U; Ercolano E; Carraro L; Blasi Roman CR; Sorba G; Canonico PL; Genazzani AA; Tron GC; Billington RA
    ChemMedChem; 2008 May; 3(5):771-9. PubMed ID: 18247435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic signatures associated with a NAD synthesis inhibitor-induced tumor apoptosis identified by 1H-decoupled-31P magnetic resonance spectroscopy.
    Muruganandham M; Alfieri AA; Matei C; Chen Y; Sukenick G; Schemainda I; Hasmann M; Saltz LB; Koutcher JA
    Clin Cancer Res; 2005 May; 11(9):3503-13. PubMed ID: 15867253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777.
    Beauparlant P; Bédard D; Bernier C; Chan H; Gilbert K; Goulet D; Gratton MO; Lavoie M; Roulston A; Turcotte E; Watson M
    Anticancer Drugs; 2009 Jun; 20(5):346-54. PubMed ID: 19369827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD
    Guo J; Lam LT; Longenecker KL; Bui MH; Idler KB; Glaser KB; Wilsbacher JL; Tse C; Pappano WN; Huang TH
    Biochem Biophys Res Commun; 2017 Sep; 491(3):681-686. PubMed ID: 28756225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Local Targeting of NAD
    Li M; Kirtane AR; Kiyokawa J; Nagashima H; Lopes A; Tirmizi ZA; Lee CK; Traverso G; Cahill DP; Wakimoto H
    Cancer Res; 2020 Nov; 80(22):5024-5034. PubMed ID: 32998997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of Nampt in gastric cancer and chemopotentiating effects of the Nampt inhibitor FK866 in combination with fluorouracil.
    Bi TQ; Che XM; Liao XH; Zhang DJ; Long HL; Li HJ; Zhao W
    Oncol Rep; 2011 Nov; 26(5):1251-7. PubMed ID: 21743967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EIF2A-dependent translational arrest protects leukemia cells from the energetic stress induced by NAMPT inhibition.
    Zucal C; D'Agostino VG; Casini A; Mantelli B; Thongon N; Soncini D; Caffa I; Cea M; Ballestrero A; Quattrone A; Indraccolo S; Nencioni A; Provenzani A
    BMC Cancer; 2015 Nov; 15():855. PubMed ID: 26542945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-proliferation effect of APO866 on C6 glioblastoma cells by inhibiting nicotinamide phosphoribosyltransferase.
    Zhang LY; Liu LY; Qie LL; Ling KN; Xu LH; Wang F; Fang SH; Lu YB; Hu H; Wei EQ; Zhang WP
    Eur J Pharmacol; 2012 Jan; 674(2-3):163-70. PubMed ID: 22119381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitor of Nicotinamide Phosphoribosyltransferase Sensitizes Glioblastoma Cells to Temozolomide via Activating ROS/JNK Signaling Pathway.
    Feng J; Yan PF; Zhao HY; Zhang FC; Zhao WH; Feng M
    Biomed Res Int; 2016; 2016():1450843. PubMed ID: 28097126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis.
    Hasmann M; Schemainda I
    Cancer Res; 2003 Nov; 63(21):7436-42. PubMed ID: 14612543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NAD metabolism fuels human and mouse intestinal inflammation.
    Gerner RR; Klepsch V; Macheiner S; Arnhard K; Adolph TE; Grander C; Wieser V; Pfister A; Moser P; Hermann-Kleiter N; Baier G; Oberacher H; Tilg H; Moschen AR
    Gut; 2018 Oct; 67(10):1813-1823. PubMed ID: 28877980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On-target effect of FK866, a nicotinamide phosphoribosyl transferase inhibitor, by apoptosis-mediated death in chronic lymphocytic leukemia cells.
    Gehrke I; Bouchard ED; Beiggi S; Poeppl AG; Johnston JB; Gibson SB; Banerji V
    Clin Cancer Res; 2014 Sep; 20(18):4861-72. PubMed ID: 25172933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic and tumor biological aspects of the anticancer nicotinamide phosphoribosyltransferase inhibitor FK866 in resistant human colorectal cancer cells.
    Ogino Y; Sato A; Uchiumi F; Tanuma SI
    Genomics; 2019 Dec; 111(6):1889-1895. PubMed ID: 30582964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of NAMPT markedly enhances plasma-activated medium-induced cell death in human breast cancer MDA-MB-231 cells.
    Nagaya M; Hara H; Kamiya T; Adachi T
    Arch Biochem Biophys; 2019 Nov; 676():108155. PubMed ID: 31628926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of NAMPT decreases cell growth and enhances susceptibility to oxidative stress.
    Xu R; Yuan Z; Yang L; Li L; Li D; Lv C
    Oncol Rep; 2017 Sep; 38(3):1767-1773. PubMed ID: 28714034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The nicotinamide phosphoribosyltransferase: a molecular link between metabolism, inflammation, and cancer.
    Gallí M; Van Gool F; Rongvaux A; Andris F; Leo O
    Cancer Res; 2010 Jan; 70(1):8-11. PubMed ID: 20028851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FK866 compromises mitochondrial metabolism and adaptive stress responses in cultured cardiomyocytes.
    Oyarzún AP; Westermeier F; Pennanen C; López-Crisosto C; Parra V; Sotomayor-Flores C; Sánchez G; Pedrozo Z; Troncoso R; Lavandero S
    Biochem Pharmacol; 2015 Nov; 98(1):92-101. PubMed ID: 26297909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.